Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bonnie Earley

Nurse Practitioner, Acute Care Meridian, MS Nurse Practitioner

NPI 1912981085 CMS profile 10608562

4909 Great River Dr, Meridian, MS 39305

Open in the dashboard

General payments

$2,470

115 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bonnie Earley of Meridian, MS is reported in the CMS Open Payments database as having received $2,470 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $586 25
2024 General $567 26
2023 General $900 40
2022 General $155 9
2021 General $262 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bonnie Earley
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Bonnie Earley were reported at $586. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Bonnie Earley Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $262 $123 $38–$327 $132
2022 $155 $130 $44–$369 $149
2023 $900 $144 $49–$410 $160
2024 $567 $146 $48–$433 $164
2025 $586 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Merck Sharp & Dohme Corporation $594 25 payments
  2. Janssen Pharmaceuticals, Inc $395 21 payments
  3. Abbott Laboratories $275 12 payments
  4. E.R. Squibb & Sons, L.L.C. $212 11 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $188 10 payments
  6. AstraZeneca Pharmaceuticals LP $169 9 payments
  7. Lexicon Pharmaceuticals, Inc. $125 6 payments
  8. Medtronic, Inc. $122 2 payments
  9. Novartis Pharmaceuticals Corporation $89 5 payments
  10. Pfizer Inc. $68 5 payments
  11. Other $232 9 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,470 115 payments
Products named General payments · program years 2021–2025
  1. VERQUVO Cardiovascular $744 32 payments
  2. XARELTO $395 21 payments
  3. VERQUVO Cardiovascular $234 9 payments
  4. LifeVest $188 10 payments
  5. FARXIGA $154 8 payments
  6. ELIQUIS $126 7 payments
  7. Xience Skypoint $95 4 payments
  8. CAMZYOS $87 4 payments
  9. SYMPLICITY G3 $75 1 payment
  10. XIENCE SIERRA $74 3 payments
  11. Other $598 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

252

Median for Nurse Practitioner: 389

Drug cost

$13,928

Median for Nurse Practitioner: $21,885

Branded share of claims

34.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 23 $12,746
Rosuvastatin Calcium Generic 35 $250
Clopidogrel Clopidogrel Bisulfate Brand 33 $235
Atorvastatin Calcium Generic 17 $132
Nitroglycerin Generic 17 $117
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 12 $87
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 18 $83
Losartan Potassium Generic 16 $72
Metoprolol Tartrate Generic 24 $58
Carvedilol Generic 20 $55

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$24,216

Medicare's payments for the services billed

Medicare patients

182

Average age 76

Services billed

331

95 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Arthritis 72%
Ischemic heart disease 68%
Atrial fibrillation 62%
Chronic kidney disease 61%
Diabetes 59%
COPD 47%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $150
$150 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $76
$76 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $47
$47 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $37
$37 23 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record